Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Specialist in Reno, NV
NPI: 1407891534Primary Practice Location
Center of Hope
5465 Reno Corporate Dr, Reno, NV
Primary Employer
Center of Hope
centerofhopeinc.org
HQ Phone
Get M.D. Peter's Phone NumberMobile
Get M.D. Peter's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
1991 - 2027
NV State Medical License
1998 - 2027
FL State Medical License
2018 - 2020
MN State Medical License
1994 - 1998
NV State Medical License
American Board of Obstetrics and Gynecology
Obstetrics & Gynecology
American Board of Obstetrics and Gynecology
Gynecologic Oncology
Drexel University College Of Medicine
drexel.edu
Medical School
Until 1990
Mayo Clinic Alix School of Medicine - Rochester
college.mayo.edu
Fellowship • Gynecologic Oncology
1994 - 1997
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Residency • Obstetrics and Gynecology
1990 - 1994
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Authors: Mike Janicek, Jeffrey Hines, Alan Gordon, Datchen Tai, Michael Teneriello
Journal: Gynecol Oncol
Publication Date: 2011-10-05
Absence of mutations in DNA mismatch repair genes in sporadic endometrial tumors with microsatellite instability.
Authors: William Cliby
Publication Date: 1996-11
Lead Sponsor: Genelux Corporation
Collaborators: GOG Foundation
Intervention / Treatment: BIOLOGICAL: olvimulogene nanivacirepvec, DRUG: Platinum chemotherapy: carboplatin (preferred) or cisplatin, DRUG: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, DRUG: Bevacizumab (or biosimilar)
Lead Sponsor: ImmunoGen, Inc.
Intervention / Treatment: DRUG: Mirvetuximab Soravtansine
Lead Sponsor: Gynecologic Oncology Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, OTHER: Questionnaire Administration, OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Paclitaxel, OTHER: Placebo Administration, DRUG: Metformin Hydrochloride
